ADUC
LIVE

Serial Number

79429112

Owner

KOWA COMPANY LTD.

Filing Date

May 20, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ADUC Trademark

Serial Number: 79429112 • Registration: 8073026

ADUC is a trademark filed by KOWA COMPANY LTD. on May 20, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

KOWA COMPANY LTD. (410 trademarks)

NO. 4-14 CHOME
TOKYO 103 , JP

Entity Type: 03

Trademark Details

Filing Date

May 20, 2025

Registration Date

December 23, 2025

Published for Opposition

November 4, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; veterinary preparations for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; vaccines for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; therapeutic medicines for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; therapeutic antibodies for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases.

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 22, 2026 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 23, 2025 R.PR
PUBLISHED FOR OPPOSITION
Nov 4, 2025 PUBO
NOTICE OF PUBLICATION
Oct 29, 2025 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 2, 2025 CNSA
ASSIGNED TO EXAMINER
Oct 1, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 14, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 11, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 31, 2025 REPR